### THE **MEDTECH INDUSTRY** 2024





**Export-oriented and competitive** 

Characterised by small and medium-sized enterprises

Research-intensive and highly

innovative

**Crisis-resistant** 

High turnover and job creator

Medtech »made in Germany« leading in the EU, second in the world

## **SPECTARIS: Our Mission**

#### Sustainable strengthening of a competitive and innovation-friendly medical technology industry in Germany

• The medical technology section of the German Industry Association SPECTARIS aims to improve the general conditions for medical technology companies. It drives forward the creation of suitable framework conditions for companies' business activities while also promoting the medtech sector as an attractive industry to work at to younger generations. SPECTARIS further proposes various improvements of the infrastructural conditions.



Source: SPECTARIS





Turnover 2022

**Domestic** oillion euros

**Abroad** oillion euro total

**67.1**%


Source: SPECTARIS, Statistisches Bundesamt

including small businesses: 47.31 billion et 12,090 enterprises, 243,800 employees

Employees 159,752 Companies 1,467

In 2022, around 1,470 German medical technology manufacturers generated a total turnover of 38.4 billion euros. With an export ratio of more than 67 %, domestic sales amounted to 12.6 billion euros while foreign business reached a value of 25.8 billion

Continuing the trends of previous years, the number of employees increased in 2022. The total number of employees amounting to 160,000 represents an increase of 3.3 % compared to the previous year. When including small businesses, a total of 12,090 companies with 243,800 employees generated a total turnover of 47.31 billion euros (2020).



### Distinct medium-sized core

100-249

**Employees Employees Employees Employees Employees** 159,752

The size structure of the German medical technology manufactures reveals a balanced industry consisting of global players and a strong core of medium-sized companies. The industry is further complemented by around 10,600 small companies which employ roughly 84,000 people.

**Employees** 

Companies

950

2.58

27,774

20-49

234

2.48

17,804

50-99

23,517

160

4.21

90,657

250 and more

29.12

1,467

38.39

Total



€ 8.0 bn

## Regional focus

Allocation of medical technology manufacturing companies In terms of number of manufacturers and total turnover,

Baden-Württembarg and Bavaria occupy the top positions in Germany, followed by Hesse, Schleswig-Holstein and North Rhine-Westphalia.

Legend: Turnover

## Contact



MEDICAL TECHNOLOGY.

www.spectaris.de

SPECTARIS - German Industry Association for Optics, Photonics, Analytical and Medical Technology e.V. Werderscher Markt 15 I 10117 Berlin T: +49 (0)30 41 40 21-0 medizintechnik@spectaris.de




Head of Medical Technology Division Marcus Kuhlmann T: +49 (0)30 41 40 21-17 kuhlmann@spectaris.de



Jörg Mayer T: +49 (0)30 41 40 21-12 mayer@spectaris.de


### Germany leading the EU

Turnover share in percent by country



In 2020 the industry generated a turnover of 95 billion euros in the European Union, 50 % of which is accounted for by German manufacturers.

# **Export-oriented** and competitive




The export quota being roughly 67 %, foreign markets play an important role for German medtech manufacturers. In 2022 37 % of exports went to countries of the European Union. On North America accounted for about 20 % of exports and in Asia around 18 %.

Experts forecast an average annual growth of 5-7 % for the global medical technology market in the coming years.

Core market in Europe, important markets in the **USA** and China

#### Health creates value

Figures in € billion



The health economy comprises the production and marketing of goods and services that serve the preservation and restoration of health.

In 2022 it was responsible for generating 12 % of Germany's gross domestic product which is equivalent to every 8th euro of German gross domestic product. At the same time, around 8.1 million people were employed in the health economy which is equivalent to every 6th job in Germany being in health economy.

The industrial health economy (iGW) as part of the health economy includes the production of pharmaceuticals and medical technology, the trade and distribution of these goods as well as scientific research. In 2022 more than 23 % of the value added in the German health economy were provided by the iGW.

### Research-intensive and highly innovative






In 2022, Germany ranked second regarding the number of applications for medical technology patents in Europe, only surpassed by the number of applications from the USA. In general, medical technology continues to be the subject of the largest share of patent applications at the European Patent Office.

In 2022, the medical technology took the second place after digital communication in terms of applications filed at the European Patent Office: 15,683 (+1%) of the total over 193,460 applications were assigned to this area. German manufacturers spend 9 % of their turnover on research and development.

0/0 R&D quota

#### Medical devices are not pharmaceuticals Medical devices differ fundamentally from medici-




nal products especially with regard to their effects, the legal requirements for market authorisation, safety requirements, innovation cycles and market surveillance requirements. Medical devices include, among other things,

apparatus, objects, substances and also software that are used for therapeutic or diagnostic purposes for human beings, where the main intended effect is unlike drugs, is not primarily pharmacological, metabolic or immunological, but mostly physical or physicochemical.

>400,000

#### Classification of medical devices **CLASSES**



regard to »Vulnerability of the human body«. There are a total of four classes with an increasing level of risk. The correct classification is the responsibility of the manufacturer. The regulatory requirements in the context of market access, e.g. in clinical trials, increase with the risk class.